Tumours not expressing an abundance of SSTR-2 over SSTR-5 subtypes may have reduced response to these agents and may, in fact, experience preferential suppression of glucagon over insulin, leading to hypoglycaemia (Bertherat et al. 2003). This evidence concerns the gene SSTR5 and neoplasm.